

VERSION 4 DEC 13, 2022

IN DEVELOPMENT

Monkeypox virus multiplexed PCR amplicon sequencing (PrimalSeq) V.4

COMMENTS 0

DOI

dx.doi.org/10.17504/protocols.io.5qpvob1nbl4o/v4

Nicholas F.G. Chen*¹, Luc Gagne*²,
Matthew Doucette², Sandra Smole²,
Erika Buzby², Joshua Hall², Stephanie Ash²,
Rachel Harrington², Seana Cofsky²,
Selina Clancy², <u>Curtis J Kapsak</u>³,
<u>Joel Sevinsky</u>³, <u>Kevin Libuit</u>³, <u>mallery.breban</u>¹,
Chrispin Chaguza¹, Nathan D. Grubaugh¹,
Daniel J. Park⁴, Glen R. Gallagher#²,
Chantal B.F. Vogels#¹

⁴Broad Institute, Cambridge, Massachusetts



Nathan Grubaugh

Department of Epidemiology of Microbial Diseases, Yale Schoo...

DISCLAIMER

DISCLAIMER - FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to <u>protocols.io</u> is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with <u>protocols.io</u>, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

ABSTRACT

Version 4 Updates:

Added a fork to the primer preparation step for use with pre-pooled primers (Yale hMPXV Amplicon Panel) from IDT

Complete validation study: https://doi.org/10.1101/2022.10.14.22280783

Background: The current global outbreak of human Monkeypox virus (hMPXV) concurrent with an ongoing SARS-CoV-2 pandemic has further highlighted the need for genomic surveillance and pathogen whole genome sequencing. While metagenomic and hybrid capture sequencing approaches were used to sequence many of the early mpox cases, the viability of



1

¹Department of Epidemiology of Microbial Diseases, Yale School of Public Health;

²Massachusetts Department of Public Health;


³Theiagen Genomics;

these methods is dependent on samples with high viral DNA concentrations. Given the atypical clinical presentation of cases associated with the current outbreak and uncertainty regarding viral load across both the course of infection and anatomical body sites, there is a strong need for a more sensitive and broadly applicable sequencing approach. Amplicon-based sequencing (PrimalSeq) was initially developed for sequencing of Zika virus, and later adapted as the main sequencing approach for SARS-CoV-2. Here, we used PrimalScheme to design a primer scheme for hMPXV and we validated it with widely used SARS-CoV-2 sequencing protocols. Based on initial validation, our approach shows notably higher depth and breadth of coverage across the genome, particularly with higher PCR cycle threshold (Ct) samples, as compared to metagenomic sequencing. While further testing is needed, the early success of this approach has significant implications for sequencing efforts of the current hMPXV outbreak and serves as a proof of concept of amplicon-based sequencing for use with other large-genome DNA viruses and potentially bacterial genomes.

Overview of Design: We used PrimalScheme (https://primalscheme.com/) to generate an hMPXV primer scheme using a pre-outbreak A.1 lineage reference genome (GenBank accession: MT903345). The primer scheme comprises a total of 163 primer pairs with an amplicon length ranging between 1597 and 2497 bp (average length of 1977 bp). The primer scheme is compatible with current ARTIC and COVIDSeq SARS-CoV-2 sequencing protocols, and while validated only with Illumina library prep methods and sequencing platforms, it would likely see a high degree of success with other sequencing platforms such as the Oxford Nanopore Technologies MinION.

Initial Validation: We validated our hMPXV primer scheme with clinical specimens at the Massachusetts Department of Public Health, Massachusetts State Public Health Laboratory under the IRB Project Titled "Rash Illness: Alternate Specimen Types and Sequencing" (protocol number 1917413). A total of 25 clinical specimens were included in this initial validation comprised of both throat and swabs of fluid from lesions of 8 individuals, belonging to the current outbreak-associated hMPXV B.1 lineage as determined by prior characterization at the Centers of Disease Control and Prevention. Ct values were determined with the non-variola orthopox diagnostic qPCR assay developed for use by the Laboratory Response Network (Rapid Diagnostic Testing for Response to the Monkeypox Outbreak - Laboratory Response Network, United States, May 17-June 30, 2022 | MMWR (cdc.gov)). Clinical samples ranged in cycle threshold (Ct) values from 15.03 (high viral concentration) to 34.63 (low viral concentration), and each sample was sequenced in parallel using a metagenomics approach and the provided amplicon-based approach. Extractions and sequencing analysis were performed in accordance with current biosafety guidance including extraction in a BSL-3 setting. An evaluation of site-specific biosafety practices should be developed in consultation with your organization's biosafety officer. Libraries were prepared with the Illumina DNA prep kit and sequenced on the MiSeq (v2 kit running 2x150 nt reads). Consensus genomes were generated at 10X coverage using the TheiaCoV_Illumina_PE Workflow Series on Terra.bio. An hMPXV "fork" was developed for us by Curtis Kapsak from Theiagen, which included the hMPXV reference sequence, primer scheme, and consensus genome length, and can currently be accessed at: https://github.com/theiagen/public_health_viral_genomics/tree/cjk-MPXV-theiacov. We found comparable genome coverage between amplicon and metagenomic sequencing with low Ct (<18) samples, yet a significant increase in genome coverage with amplicon sequencing in higher Ct samples (>18; Figure 1A.) The library clean up stage of the amplicon based Illumina DNA prep protocol was conducted using the 'standard DNA input' option for comparison to metagenomics. Following optimization with 15 additional paired samples unrelated to the initial 10 samples, we found improved genome coverage with higher Ct samples (>25) using the 'small PCR amplicon input' option of the Illumina DNA prep protocol (Figure 1B.) Our findings highlight how amplicon-based approaches can significantly expand hMPXV sequencing to a wider variety of samples.

Figure 1: Percent genome coverage at 10X



A. Comparison in genome coverage for 10 paired clinical samples sequenced with metagenomics and amplicon approaches using the v1 standard DNA input library clean up method. **B.** Comparison between the v2 Illumina DNA prep small PCR amplicon input and the v1 standard DNA input library clean up methods for 15 paired clinical samples

Amongst samples with a low Ct (<18), genome coverage via amplicon sequencing was consistently >97%, with minimal amplicon drop-outs (**Figure 2**). Amplicons 11, 75, and 118 showed consistent drop-out across the sequenced samples, while none of the primers had mismatches, except for a single nucleotide mismatch in the 11_RIGHT primer. We did obtain coverage for these amplicons when sequencing clade IIa DNA from cultured virus (strain USA-2003; NR-4928) obtained from BEI Resources (NIAID, NIH). This suggests that the dropouts of these primers may be a specific issue related to the current hMPXV B.1 lineage genomes. As this protocol is still in development, we will further investigate performance as we continue to sequence additional samples.




Figure 2. Depth of coverage by genome position and Ct value for 10 clinical specimens sequenced using the amplicon-based sequencing approach.

Conclusion: We developed an amplicon-based sequencing (PrimalSeq) approach for hMPXV that improved the depth and breadth of genome coverage with low viral concentration specimens as compared to metagenomic sequencing.

This protocol represents the fourth iteration of development. Further versions will be uploaded to protocols.io with an accompanying description of changes as appropriate.

DOI

dx.doi.org/10.17504/protocols.io.5qpvob1nbl4o/v4

PROTOCOL CITATION

Nicholas F.G. Chen*, Luc Gagne*, Matthew Doucette, Sandra Smole, Erika Buzby, Joshua Hall, Stephanie Ash, Rachel Harrington, Seana Cofsky, Selina Clancy, Curtis J Kapsak, Joel Sevinsky, Kevin Libuit, mallery.breban, Chrispin Chaguza, Nathan D. Grubaugh, Daniel J. Park, Glen R. Gallagher#, Chantal B.F. Vogels# 2022. Monkeypox virus multiplexed PCR amplicon sequencing (PrimalSeq) . protocols.io

1

https://dx.doi.org/10.17504/protocols.io.5qpvob1nbl4o/v4 Version created by Nathan Grubaugh

KEYWORDS

Monkeypox, MPXV, Amplicon sequencing, PrimalSeq, hMPXV

LICENSE

This is an open access protocol distributed under the terms of the <u>Creative Commons</u>

<u>Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Dec 12, 2022



4

Citation: Nicholas F.G. Chen*, Luc Gagne*, Matthew Doucette, Sandra Smole, Erika Buzby, Joshua Hall, Stephanie Ash, Rachel Harrington, Seana Cofsky, Selina Clancy, Curtis J Kapsak, Joel Sevinsky, Kevin Libuit, mallery.breban, Chrispin Chaguza, Nathan D. Grubaugh, Daniel J. Park, Glen R. Gallagher#, Chantal B.F. Vogels# Monkeypox virus multiplexed PCR amplicon sequencing (PrimalSeq)ÃÂ https://dx.doi.org/10.17504/protocols.io.5gpvob1nbl4o/v4

LAST MODIFIED

Dec 13, 2022

PROTOCOL INTEGER ID

73877

MATERIALS TEXT

MPXV Primer Scheme

Primers may be ordered from any oligonucleotide company using the following file as a reference. For instructions on how to prepare hMPXV Primer Pool 1 and 2 (10 uM) see the "Unpooled Primers" fork of step 1 in the protocol.

MPXV-primer_genome-positions.tsv

Our pre-pooled primer scheme can also be ordered through Integrated DNA Technologies (IDT) with the following link. For preparation instructions, follow the "IDT Pre-Pooled Primers" fork of step 1 in the protocol. https://go.idtdna.com/Yale-Mpox-Amplicon-Panel-Request-Consult.html

Library Preparation Method: Illumina DNA Prep

Reagents: https://www.illumina.com/products/by-type/sequencing-kits/library-prep-kits/nextera-dna-flex.html https://www.neb.com/products/m0494-q5-hot-start-high-fidelity-2x-master-mix#Product%20Information

Library Preparation Method: CovidSeq

Reagents: https://www.illumina.com/products/by-type/ivd-products/covidseq.html

A	В	С				
Illumina COVIDSeq Test Box 1 – 3072 Samples, Part # 20044408						
Reagent	Description	Storage				
ITB	Illumina Tune Beads	Room Temperature				
ST2 HT	Stop Tagment Buffer 2 HT	Room temperature, post-am				
Illumina COVIDSeqTest Box 2 – 3072 Samples, Part # 20044409						
EBLTS HT	Enrichment BLT HT	2°C to 8°C post-amp environ				
TWB HT	Tagmentation Wash Buffer H	2°C to 8°C post-amp environ				
RSB HT	Resuspension Buffer HT	2°C to 8°C, post-amp enviror				
Illumina COVIDSeq Test Box	3 – 3072 Samples, Part # 200	044410				
IPM HT	Enhanced PCR Mix HT	-25°C to -15°C, pre-amp envi				
TB1 HT	Tagmentation Buffer 1 HT	-25°C to -15°C, post-amp env				
EPM HT	Enhanced PCR Mix HT	-25°C to -15°C, pre-amp envi				
Index Adapater Part Numbers : 20043132, 20043133, 20043134, 20043135						



A	В	С
Index Adapters	IDT for Illumina- PCR Indexes	Room Temperature

Additional Materials

A	В	С
Reagent	Description	Storage
80% EtOH	80% Ethanol	Room Temperatur
Nuclease-free wate		Room Temperatur

SAFETY WARNINGS

Processing of any sample type which could potentially be positive for hMPXV should be conducted in BSL2+ settings. Before starting work with these samples, please contact your local EHS (environment, health and safety) or biosafety office for proper guidance on how to work with these samples in your laboratory.

DISCLAIMER

DISCLAIMER - FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to <u>protocols.io</u> is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with <u>protocols.io</u>, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

BEFORE STARTING

This protocol is currently in the developmental phase. It is for research purposes only and should not be used in a diagnostic capacity.

If using clinical samples, DNA will need to be extracted and purified prior to beginning library preparation.

Primer diluting and pooling requires several hours and may be conducted well in advance so long as the pooled primers are stored at -20°C.

protocols.io

6

Citation: Nicholas F.G. Chen*, Luc Gagne*, Matthew Doucette, Sandra Smole, Erika Buzby, Joshua Hall, Stephanie Ash, Rachel Harrington, Seana Cofsky, Selina Clancy, Curtis J Kapsak, Joel Sevinsky, Kevin Libuit, mallery.breban, Chrispin Chaguza, Nathan D. Grubaugh, Daniel J. Park, Glen R. Gallagher#, Chantal B.F. Vogels# Monkeypox virus multiplexed PCR amplicon sequencing (PrimalSeq)ÃÂ https://dx.doi.org/10.17504/protocols.io.5gpvob1nbl4o/v4

Following primer dilution and pooling, this workflow can be completed in one day, however, it is recommended to be conducted across two, with the amplicon generation step on the first day and all subsequent wet-lab steps on the second day.

Protocol Recommendations:

To maximize sequencing coverage, we recommend the following best practices based on our multi-site validation study:

- 1. Prioritizing samples with cycle threshold (Ct) values <29 if resources are limited
- 2. Generating at least 1 million sequencing reads per sample

Primer Preparation

Step 1 includes a Step case.

IDT Pre-Pooled Primers

Unpooled Primers

Primer Source

step case

IDT Pre-Pooled Primers

Integrated DNA Technologies (IDT) Pre-Pooled Yale hMPXV Amplicon Panel: https://go.idtdna.com/Yale-Mpox-Amplicon-Panel-Request-Consult.html

1.1 Dilute primers to a working concentration of 10uM with nuclease-free water (i.e. 1:10 dilution)



Safe Stopping Point: Pooled Primers Can Be Stored at -20°C

2 Library Preparation Method

Step 2 includes a Step case.

Illumina CovidSeq Test (RUO)

Illumina DNA Prep Kit

Amplicon Generation

step case

Illumina CovidSeq Test (RUO)



3 Reagents:

Reagent	Storage	Instructions
MPXV Primer Pool 1 (10 uM)	-20°C	Thaw at RT
MPXV Primer Pool 2 (10 uM)	-20°C	Thaw at RT
IPM HT	-20°C	Thaw at RT

3.1 In two separate tubes, prepare the following master mixes:

Pool 1

Reagent	Volume in 20 µL master mix		
IPM HT	12.5 µL		
MPXV Primer Pool 1 (10 uM)	3.6 µL		
Nuclease-free water	3.9 µL		

Pool 2

Reagent	Volume in 20 µL master mix		
IPM HT	12.5 µL		
MPXV Primer Pool 2 (10 uM)	3.6 µL		
Nuclease-free water	3.9 µL		

Note			

- 3.2 Label two sets of PCR tubes/plates for Pool 1 and Pool 2
- 3.3 Add the following:
 - 🗸 20 µL Pool 1 master mix to each Pool 1 tube/well
 - <u>A 20 µL</u> Pool 2 master mix to each Pool 2 tube/well
- - Mix by pipetting up and down 10 times

Briefly centrifuge tubes/plates

Note

3.5 Place on thermocycler and run the following program (choose preheat lid option):



PCR Program					
Step(s)	Temperature	Time	Cycles		
Initial denaturation	98°C	3min	1		
Denaturation	98°C	15sec			
Anneal and			35 times		
extension	63°C	5min			
Hold	4°C	Hold	Hold		
Volume Amount: 25 μL		Lid: 105°C			

3.6 *Safe Stopping Point: Amplified DNA may remain in the thermocycler at 4°C or stored at -20°C until ready to use*



Amplicon Tagmentation and Clean Up

4 Reagents:

Reagent	Storage	Instructions
EBLTS HT	4°C	Thaw at RT; vortex to mix
TB1 HT	-20°C	Thaw at RT; vortex to mix
ST2 HT	RT	Vortex before use
TWB HT	4°C	Vortex before use

- 4.1 Spin down PCR tubes/plates
- 4.2 Prepare the following master mix:



Reagent	Volume in 30 µL master mix		
TB1	10 μL		
EBLTS	3.3 µL		
Nuclease-free water	16.7 µL		

- 4.3 In each PCR tube add:
 - 🗓 30 µL Master mix
 - I 10 uL Pool 1 amplicons
 - A 10 µL Pool 2 amplicons

For a total reaction volume of $~\underline{\mbox{\em L}}~50~\mu\mbox{\em L}~$ per PCR tube/well

Note			

- 4.4 Mix by pipetting up and down and briefly centrifuge
- 4.5 Place on thermocycler and run the following program (choose preheat lid option):



Temp	Time	
55°C	3 minutes	
10°C	hold	

- 4.6 Once the thermocycler reaches $$10\,^{\circ}\text{C}$$, remove tubes/plates and spin down
- 4.7 Add \perp 10 μ L ST2 to each tube/well, mix by pipetting up and down, and briefly centrifuge
- 4.8 Incubate at 8 Room temperature for © 00:05:00

5m

- 4.9 Place on magnetic stand and wait until liquid is clear (a few minutes)
- 4.10 Remove and discard all supernatant
- 4.11 Remove tubes/plates from magnetic stand and add \perp 100 μ L TWB to each tube/well
 - Mix by pipetting up and down 10 times and spin down. Be careful to not introduce bubbles.
- 4.12 Repeat steps 4.9 4.11. Leave the supernatant after the second wash so that the beads don't dry out

Amplify Tagmented Amplicons

5 Reagents:

Reagent	Storage	Instructions
EPM HT	-20°C	Invert to mix
Index adapters	-20°C	Thaw at RT; vortex to mix

5.1 Prepare the following master mix:

Reagent	Volume in 40 µL master mix
EPM	20 μL
Nuclease-free water	20 µL

- 5.2 Place the tubes/plates with tagmented amplicons on the magnetic stand and remove the supernatant once the liquid is clear
- 5.3 Use a **20µL pipette** to remove any residual TWB from tubes/wells

- 5.4 Remove the tubes/plates from the magnetic stand
- 5.5 Add \pm 40 μL master mix to each tube/well
- 5.6 Add $\underline{\text{A}}$ 10 μL dual-barcoded index adapters to each tube/well

Note			

- 5.7 Pipette up and down to mix and spin down
- 5.8 Place on thermocycler and run the following program (choose preheat lid option):



Temp	Time	Repeat	
72°C	3 minutes		
98°C	3 minutes		
98°C	20 seconds	1	
60°C	30 seconds	7 times	
72°C	1 minute		
72°C	3 minutes		
10°C	hold		

Pool and Clean Up

6 Reagents:

Reagent	Storage	Instructions
ITB	RT	Vortex thoroughly to mix
RSB HT	4°C	Bring to RT; vortex to mix
80% EtOH	RT	Prepare immediately before use

6.1 Briefly centrifuge tubes/plates



6.2	Place on magnetic stand and wait until liquid is clear (a few minutes)	
6.3	Pool libraries by equal volume:	
6.4	Pipette up and down to mix pooled libraries and briefly spin down	
6.5	Calculate the volume of ITB to reach a 0.6X beads:total pool volume ratio Note	
6.6	Mix by pipetting up and down, briefly centrifuge, and incubate at Room temperature for 00:05:00	5m
6.7	Place on magnetic stand and wait until liquid is clear (a few minutes)	
6.8	Transfer supernatant to a new tube (do not discard, this is your final library). This volume will be slightly lower than the total combined volume	

6.9



Calculate the volume of beads to add to the supernatant to attain a second clean-up beads:sample ratio of **0.9X**:


Vo = total volume of sample + beads from step 5.5 Vt = transferred volume of supernatant

Note Service S

6.10 Add **beads** to supernatant, mix by pipetting up and down, briefly centrifuge, and incubate at



- $6.11 \qquad \hbox{Place on magnetic stand and wait until liquid is clear (a few minutes)}$
- 6.12 Carefully discard supernatant



	Sequencing
7	Protocol validated on the MiSeq (v2 kit running 2x150 nt reads)
	Note
	RIGINTORMATICS/ANALYSIS
	Bioinformatics/Analysis
8	Sequencing results may be analyzed utilizing a standard amplicon sequencing bioinformatics pipeline, including those employed for SARS-CoV-2 sequencing.
8	Sequencing results may be analyzed utilizing a standard amplicon sequencing bioinformatics pipeline,
8	Sequencing results may be analyzed utilizing a standard amplicon sequencing bioinformatics pipeline, including those employed for SARS-CoV-2 sequencing.
8	Sequencing results may be analyzed utilizing a standard amplicon sequencing bioinformatics pipeline, including those employed for SARS-CoV-2 sequencing.
8	Sequencing results may be analyzed utilizing a standard amplicon sequencing bioinformatics pipeline, including those employed for SARS-CoV-2 sequencing.
8	Sequencing results may be analyzed utilizing a standard amplicon sequencing bioinformatics pipeline, including those employed for SARS-CoV-2 sequencing.